Evidence map›Paper›PMID 40877392›Full record

ArticleScientific reports2025

Regulation of divergent epithelial-to-mesenchymal transition responses via the CDK4/6-USP51 pathway through ZEB1 protein stabilization.

Yuta Sakamoto, Masataka Takahashi, Hajime Nishimura, Kazuhide Watanabe, Harukazu Suzuki

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuta SakamotoLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 230-0045, Kanagawa, Japan.
Masataka TakahashiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 230-0045, Kanagawa, Japan.
Hajime NishimuraLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 230-0045, Kanagawa, Japan.
Kazuhide WatanabeLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 230-0045, Kanagawa, Japan.
Harukazu SuzukiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, 230-0045, Kanagawa, Japan. harukazu.suzuki@riken.jp.

Funding

Japan Science and Technology Agency JPMJSP2179Japan Society for the Promotion of Science 20H04211
6 · The paper itself

Abstract

Epithelial-to-mesenchymal transition (EMT) is a cellular process important for numerous developmental processes, wound healing and cancer progression. In the context of heterogenous nature of cancer, EMT occurs at the forefront of tumor invasion, although the precise molecular mechanisms governing its spatial dynamics remain unclear. This study aimed to explore the diverse responses to EMT in monolayer cell cultures of MCF10A epithelial cell with induction of Zinc-finger E-box binding homeobox 1 (ZEB1), an EMT-inducing transcription factor. ZEB1-induced MCF10A cells exhibited EMT in space- and cell density-dependent manner. The expression of ZEB1 was modulated by the ubiquitin-proteasome pathway. We found that CDK4/6 and USP51 enhanced ZEB1 protein stability via deubiquitination. Moreover, suppressing USP51 and CDK4/6 activity attenuated cell migration, a characteristic of the mesenchymal phenotype, in ZEB1-induced MCF10A cells. Finally, we demonstrated that CDK4/6 kinase activity is important for cell migration as well as stabilizing ZEB1 in the mesenchymal breast cancer cell line MDA-MB-231. These insights could pave the way for developing more targeted and effective therapies targeting at ZEB1 and EMT in advanced cancers.

Indexed as

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Epithelial-Mesenchymal TransitionUbiquitin-Specific ProteasesZinc Finger E-box-Binding Homeobox 1Breast NeoplasmsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansProtein StabilitySignal TransductionUbiquitinationCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Ubiquitin-Specific ProteasesZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Breast cancerEpithelial-to-mesenchymal transitionZinc finger e-box binding homeobox 1 (ZEB1)

Identifiers

PMID40877392
PMCPMC12394660

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.